Evidence map›Paper›PMID 38889331›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Cordycepin Modulates Microglial M2 Polarization Coupled with Mitochondrial Metabolic Reprogramming by Targeting HKII and PDK2.

Xin Zhong, Shiqiang Gong, Linghui Meng, Weifan Yao, Ke Du, Linchi Jiao, Guowei Ma, Jingwei Liang, Binbin Wei, Xin Jin and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. AiScience · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. International journal of molecular sciences · 2026
    Review
  9. Article
  10. Cordycepin alleviates nicotine withdrawal-induced anxietyDrug and alcohol dependence reports · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Microglial polarization in retinal neovascularization: Friend or foe?Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. FTO-dependent mInflammation · 2026
    Article
  20. S100A8 aggravates sepsis-associated encephalopathy by promoting PFKFB3-dependent glycolysis and microglial neuroinflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Xin ZhongSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.ORCID 0000-0002-7327-1755
Shiqiang GongSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Linghui MengHe University, Shenyang, Liaoning, 110163, China.
Weifan YaoSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Ke DuSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Linchi JiaoSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Guowei MaSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Jingwei LiangSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Binbin WeiSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Xin JinSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Junhui TongSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Jianru DongSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Mengyu LiuSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Menglin GaoSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Huachao JiaSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Wenjuan JiangThe First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110002, China.
Zhihua YuThe Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110165, China.
Yanzhe WangThe First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110002, China.
Xiaohong SunScience Experiment Center, China Medical University, Shenyang, Liaoning, 110122, China.
Minjie WeiSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.
Mingyan LiuSchool of Pharmacy, China Medical University, Shenyang, Liaoning, 110122, China.ORCID 0000-0002-2305-8964

Funding

Doctoral Start-up Foundation of Liaoning Province 2019-BS-289Key Research and Development Program of Liaoning Province 2018225089Liaoning Provincial Science and Technology Plan Joint Plan 2023-MSLH-369Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions LJKZ0775National Natural Science Foundation of China 81901309the National Natural Science Foundation of China 81501098The Science and Technology Funding Project to support the high-quality development of China Medical University 123-3110210138
6 · The paper itself

Abstract

The microenvironment mediated by the microglia (MG) M1/M2 phenotypic switch plays a decisive role in the neuronal fate and cognitive function of Alzheimer's disease (AD). However, the impact of metabolic reprogramming on microglial polarization and its underlying mechanism remains elusive. This study reveals that cordycepin improved cognitive function and memory in APP/PS1 mice, as well as attenuated neuronal damage by triggering MG-M2 polarization and metabolic reprogramming characterized by increased OXPHOS and glycolysis, rather than directly protecting neurons. Simultaneously, cordycepin partially alleviates mitochondrial damage in microglia induced by inhibitors of OXPHOS and glycolysis, further promoting MG-M2 transformation and increasing neuronal survival. Through confirmation of cordycepin distribution in the microglial mitochondria via mitochondrial isolation followed by HPLC-MS/MS techniques, HKII and PDK2 are further identified as potential targets of cordycepin. By investigating the effects of HKII and PDK2 inhibitors, the mechanism through which cordycepin targeted HKII to elevate ECAR levels in the glycolysis pathway while targeting PDK2 to enhance OCR levels in PDH-mediated OXPHOS pathway, thereby inducing MG-M2 polarization, promoting neuronal survival and exerting an anti-AD role is elucidated.

Indexed as

DeoxyadenosinesDisease Models, AnimalMicrogliaMitochondriaAlzheimer DiseaseAnimalsGlycolysisHexokinaseMetabolic ReprogrammingMicePyruvate Dehydrogenase Acetyl-Transferring KinasecordycepinDeoxyadenosinesHexokinasePdk2 protein, mousePyruvate Dehydrogenase Acetyl-Transferring KinasecordycepinHKIImetabolic reprogrammingmicroglial polarizationPDK2

Identifiers

PMID38889331
PMCPMC11336950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.